Morningstar
Merck Drug Gets Fast-Track Designation from FDA for Alzheimer's Treatment
Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...
STAT
New data confirm Novo drug did not slow Alzheimer’s progression
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hosted on MSN
Experimental drug can sharply reduce amyloid beta's impact on Alzheimer’s
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment. Toxic proteins quietly collect inside cells, support cells turn restless, and ...
The New York Times
In New Dementia Trials, Ozempic’s ‘Miracle Drug’ Image Takes a Hit
The drug failed to slow the progression of early Alzheimer’s. Experts are trying to understand why. By Dana G. Smith and Dani Blum Over the past few years, scientists have learned that Ozempic and ...
Labroots
Experimental Drug 'NU-9' Shows Promise Against Alzheimer's
An experimental drug called NU-9 has shown promise as an early intervention for Alzheimer’s disease. The corresponding study was published in Alzheimer’s & Dementia. "Alzheimer's disease begins ...
Science Daily
A new drug could stop Alzheimer’s before memory loss begins
New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...